Last mentioned: Feb 25, 2026
Reporting Season Pressure
Difficult February reports for CSL and Sonic Healthcare extend index declines.
Anteris Funding
Anteris Technologies raises approximately $440 million for heart valve technology.
Nasdaq Biotech Peak
The index records a 30% annual gain, diverging from broader tech markets.
Record Funding Year
Clarity ($200m) and Mesoblast ($260m) complete significant capital raises.
ASX Healthcare Slump
The sector begins a calendar year decline of 25% led by major heavyweights.
The global healthcare sector is splitting into a 'two-speed' market as regulatory uncertainty under the Trump administration pressures established giants while innovative biotechs find significant capital. Despite a 25% decline in the ASX 200 healthcare index, smaller players are leveraging AI and record-setting capital raises to navigate a complex FDA landscape.
The global biotech sector has diverged into a 'two-speed' market, where innovative drug discovery and device firms are outperforming established healthcare heavyweights. Despite regulatory uncertainty under the Trump administration and a 25% decline in the ASX 200 healthcare sector, the Nasdaq Biotech Index has surged 30%, supported by record-breaking capital raises.
The global healthcare sector is bifurcating as mid-cap biotech innovators outperform established heavyweights despite regulatory headwinds from the Trump administration. While the ASX 200 healthcare index fell 25% in 2025, a surge in capital raising and AI integration is fueling a resilient 'engine room' of drug discovery and device innovation.